Trevi Therapeutics plans two pivotal phase III trials for IPF-related chronic cough as FDA alignment achieved (NASDAQ:TRVI)

Trevi Therapeutics (TRVI) Q4 2025 earnings call: FDA-aligned Phase III IPF cough plans, trial timelines, cash runway to 2028, key risks—read now.

You will be redirected in 10 seconds.